What's Up And Coming At Revolo Biotherapeutics?
Source: Bioprocess Online
Revolo’s plans for 2025 include expanding clinical trials for its lead eosinophilic esophagitis candidate and developing a sublingual delivery method.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more